Related Experiment Video
Updated: Oct 12, 2025
12:04
The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
Published on: November 1, 2015
18.0K
TLR7 Signaling in Lupus B Cells: New Insights into Synergizing Factors and Downstream Signals
1Department of Internal Medicine, Rheumatic Diseases Division and Department of Immunology, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-8884, USA. anne.satterthwaite@utsouthwestern.edu.
Current Rheumatology Reports
|November 24, 2021
Summary
Toll-like receptor 7 (TLR7) signaling in B cells drives systemic lupus erythematosus (SLE) by promoting autoreactive responses. Understanding TLR7 pathways reveals new therapeutic targets for SLE.
Area of Science:
- Immunology
- Molecular Biology
Background:
- Systemic lupus erythematosus (SLE) pathogenesis involves nucleic acid-containing antigens activating endosomal Toll-like receptors (TLRs).
- B cell activation is a key driver of SLE autoimmunity.
Purpose of the Study:
- To review recent advances in understanding Toll-like receptor 7 (TLR7) signaling in B cells.
- To explore how TLR7 activation contributes to SLE development and autoimmunity.
Main Methods:
- Review of current literature on TLR7 signaling pathways in B cells.
- Analysis of genetic associations and functional roles of TLR7 pathway components in SLE.
Main Results:
- TLR7 signaling, in conjunction with cytokines like IFNγ and IL-21, promotes autoreactive germinal centers and specific B cell subsets (ABC/DN2).
- BAFF and type 1 IFNs amplify autoantibody production from transitional B cells via TLR7.
- Genetic factors (STAT1, BANK1, IRF5, SLC15A4, CXorf21/TASL) and proper TLR7 trafficking are critical for SLE development.
Conclusions:
- TLR7 signaling is a central mechanism in SLE pathogenesis, particularly within B cells.
- Insights into TLR7 pathways offer promising avenues for novel SLE therapeutics.
- Several potential TLR7-targeted therapies are under investigation in preclinical and clinical studies.
More Related Videos
Related Concept Videos
01:24T Cell Types and Functions
1.5K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.5K
01:20The JAK-STAT Signaling Pathway
9.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.6K
01:16TGF - β Signaling Pathway
8.0K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
8.0K